Wellness brand Maxine+Morgan is launching a clinical study to investigate the effectiveness of its custom herbal blend of CBD, turmeric, ginger and other natural ingredients for menstrual symptom relief.
In a three-month long, blind placebo-controlled study, participants will record their pain levels and quality of life twice a day.
At random, the 70 participants will receive a Maxine+Morgan herbal supplement, Ibuprofen, and placebo in order to compare results.
"With the clinical study, we're hoping to continue the conversation around women's wellness and ways in which we can use the amazing healing qualities of naturally derived herbs to influence an uninterrupted lifestyle,” Ariel Morgan, CEO and president of Maxine+Morgan, told Benzinga. “It's important to us that we leverage our resources and invest in research, analysis and experiential data to efficiently support our consumers needs.”
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
The Benzinga Cannabis Capital Conference is coming to Florida
The Benzinga Cannabis Capital Conference is returning to Florida, in a new venue in Hollywood, on April 16 and 17, 2024. The two-day event at The Diplomat Beach Resort will be a chance for entrepreneurs, both large and small, to network, learn and grow. Renowned for its trendsetting abilities and influence on the future of cannabis, mark your calendars – this conference is the go-to event of the year for the cannabis world.
Get your tickets now on bzcannabis.com – Prices will increase very soon!